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Background
Vaccination has proven itself as the most effective tool
to control and prevent the disease and to facilitate the
safe trade of live animals.
Viral vaccine manufacturing processes present some
specific constraints as compared to other biotech pro-
ducts linked to the cell substrate used and to the viral
production.
Multiple cell lines are used for productions such as
VERO, MDCK, MRC5, BHK, and CHO cells. BHK-21
cells were selected because they are the most commonly
used cells for vaccine production.
As the feasibility of transferring the BHK-21 cells
growth in microcarriers from a conventional bioreactor
to single-use bioreactor (SU) was demonstrated, actually
was time to scale-up and verify the flexibility and ease
of use of these SU bioreactors enable rapid scale-up
without any loss in product quality. This document
describes a scaled-up production of a bovine viral
vaccine.
Identification of optimal parameters values, testing at
intermediary bioreactors scales (2 liters - 50 liters) and
application of the new process settings at industrial
bioreactor scale of 200 liters were performed. Taking
into account that a critical feature of microcarrier-based
cell culture is the homogeneity of cell adhesion to the
beads, mixing and aeration performance evaluation
remain mandatory to ensure robust scale-up of cell cul-
ture processes.
The goal of this study was to evaluate the possibility
to produce the antigens for animal vaccines manufactur-
ing in a bioreactor SU as alternative to roller bottles
without any loss in product quality. Evaluation of COG
reduction was done.
Materials and methods
Selection of appropriate culture conditions can be
important to achieve consistent cell culture and virus
production across sites and scales. Because characteris-
tics like tank geometry and hardware (impellers, sparger)
are not subject to change during scale-up, the scalability
from 2L to 200L in the BIOSTAT® STR bioreactor was
an easy strategy for our production process.
Several studies were conducted to compare the growth
of BHK-21 cells in microcarriers.
Identification of optimal parameters values and testing
at intermediary bioreactor scales (2 liters - 50 liters).
Application of the new process settings at industrial fer-
mentor scale (200 liters)
For the scale down models, the cultures were con-
ducted with:
- Biostat B plus and Bisotat B (Sartorius-stedim): Uni-
vessel® SU 2L biorector and conventional bioreactor
with glass vessels of 10L.
- BIOSTAT® CultiBag STR 50 L
- BIOSTAT® CultiBag STR 200 liters
Cultures were regularly sampled to monitor the in-
process parameters such as final cell concentration and
product yield (TCID50/ml titration). In this study, these
performances were evaluated.
Finally, taking into account that for vaccine formula-
tion microcarriers must be eliminated from the viral
suspension, filtration through Sartopure PP2 cartridges
(from Sartorius Stedim Biotech ) was performed.
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Results
The most important process criterion for evaluating the
performance of each size of bioreactor is their ability to sup-
port the same level of viral production as in a conventional
bioreactor. To evaluate this point, antigen production for
a bovine vaccine was produced in the different bioreactors.
• Comparable results between 2L, 10L, 50L and 200L
concerning cell density, viability, productivity and
product quality (Figure 1).
• Bioreactor system allows even equivalent cell
growth profiles and equivalent cell population
homogeneity on microcarriers.
• Good cell attachment and propagation.
• Very accurate pO2 control in BIOSTAT CultiBag
STR 50 and 200L. Good gas transfer capacity neces-
sary to decrease the amount of oxigen needed to
mantain the dissolved-oxygen concentration in the
set point selected. Good agitation and easy speed
calculation according scale-up.
Figure 1 Results of cell culture and infectivity at 200L scale.
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• Viral production obtained with large scale bioreac-
tors was equivalent to the one obtained with the
Univessel SU 2L bioreactor (Figure 1).
• One concern for the bovine viral vaccine prepara-
tion is how to eliminate microcarriers retaining the
cellular debris, several assays filtrating through Sarto-
pure PP2 or PP3 cartridges were performed obtaining
no significant drop in virus titer.
Conclusions
• Linear scalability from R&D to manufacturing.
• SU Bioreactors offer similar growth and productiv-
ity than conventional bioreactors or roller bottles
but are more flexible.
• SU Bioreactors have a faster turnaround time
between batches because there is much less cleaning
and sterilizations.
• SU Bioreactors are the best solution when contain-
ment is required (BSL-3 laboratories).
• Comparable results between 2L, 10L, 50L and
200L:
Cell density ⇒ Viability ⇒ Productivity ⇒ Pro-
duct quality.
• Good agitation and easy speed calculation accord-
ing scale-up.
• Bioreactor system allows even.
• Equivalent cell growth profiles.
• Equivalent cell population homogeneity on micro-
carriers. Good cell attachment and propagation.
Therefore offering a suitable process to produce our
bovine vaccine using attachment dependent cells.
Next potential goal: Reduction COG
• Reducing number of RB needed to inoculate the
bioreactor and increasing virus yields.
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Figure 2 Comparison of cell growth and virus production in 2 and 10L bioreactors and in a BIOSTAT®CultiBag STR 50 and 200L SU.
Garcia et al. BMC Proceedings 2015, 9(Suppl 9):P76
http://www.biomedcentral.com/1753-6561/9/S9/P76
Page 3 of 3
